Agilent Technologies, a leader in analytical and clinical laboratory technologies, has agreed to acquire Biocare Medical for $950 million.
The acquisition will enhance Agilent’s immunohistochemistry offering and expand its ability to serve a broad range of pathology labs across clinical and research settings.
Biocare Medical is a leader in immunohistochemistry and molecular pathology solutions focused on advancing cancer diagnostics and research. The company has more than 300 specialized antibodies and a proven R&D capability.
The S&C team representing Agilent was led by Pete Jones and Greg Travers.